BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $19.50 Average Price Target from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have received a consensus rating of “Moderate Buy” from the fourteen analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $19.50.

Several research firms have recently weighed in on BCRX. Needham & Company LLC reduced their price objective on BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Zacks Research downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. JMP Securities lifted their price target on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a research note on Wednesday, October 15th. Barclays reduced their price objective on shares of BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, December 29th.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 91,004 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $7.10, for a total transaction of $646,128.40. Following the transaction, the insider directly owned 416,152 shares in the company, valued at approximately $2,954,679.20. The trade was a 17.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 183,453 shares of company stock valued at $1,330,965. Company insiders own 5.10% of the company’s stock.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in BioCryst Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after buying an additional 482,494 shares during the period. Deerfield Management Company L.P. grew its stake in BioCryst Pharmaceuticals by 159.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after acquiring an additional 7,477,000 shares in the last quarter. State Street Corp grew its stake in BioCryst Pharmaceuticals by 8.9% during the 2nd quarter. State Street Corp now owns 8,505,392 shares of the biotechnology company’s stock valued at $76,208,000 after acquiring an additional 691,988 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of BioCryst Pharmaceuticals by 22.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 5,225,986 shares of the biotechnology company’s stock valued at $39,665,000 after purchasing an additional 947,431 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of BioCryst Pharmaceuticals by 1.9% in the second quarter. Geode Capital Management LLC now owns 5,054,610 shares of the biotechnology company’s stock worth $45,296,000 after purchasing an additional 93,973 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $6.38 on Monday. The firm’s 50 day moving average is $7.22 and its 200-day moving average is $7.52. BioCryst Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $11.31. The stock has a market capitalization of $1.34 billion, a P/E ratio of -127.60, a P/E/G ratio of 0.42 and a beta of 0.83.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.